Investors & News

Investor Relations

Ascendis Pharma is applying its innovative prodrug technology to build a leading, fully integrated rare disease company focused on making a meaningful difference in patients’ lives. The company utilizes its TransCon technology with clinically validated parent drugs to create new therapies with potential for best-in-class efficacy, safety and/or convenience. Ascendis Pharma has a wholly-owned pipeline of three rare disease endocrinology product candidates in clinical development.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.05 (0.08%)
Data as of 09/24/18 9:30 a.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $66.45 with a 52 week high of $76.99 and a 52 week low of $31.56.
Recent NewsMore >>
Ascendis Pharma A/S Announces Support for Children’s Growth Awareness Week and Day 2018
Ascendis Pharma A/S Announces Presentations on Technology and Rare Disease Endocrinology Pipeline at September Conferences
Ascendis Pharma A/S Announces Upcoming Investor Presentations
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.